Market research
DXR Daxor Corporation
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 58M
- P/E ratio
- 6.1
- Analyst target
- 22.5
- Dividend yield
- Not available
- Beta
- 0.27
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- US2394671034
- Market cap
- 58M
- P/E ratio
- 6.1
- Analyst target
- 22.5
- Dividend yield
- Not available
- Beta
- 0.27
About
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DXR discussion.
5 years, 4 months ago
Daxor Corporation is currently in a long term downtrend where the price is trading 13.1% below its 200 day moving average.
From a valuation standpoint, the stock is 990.0% more expensive than other stocks from the Financial Services sector with a price to sales ratio of 98.8.
Daxor Corporation's total revenue sank by 22.3% to $145K since the same quarter in the previous year.
Its net income has increased by 297.8% to $2M since the same quarter in the previous year.
Finally, its free cash flow fell by 118.2% to $-555K since the same quarter in the previous year.
Based on the above factors, Daxor Corporation gets an overall score of 1/5.